Review
Orthopedics
Lianghai Jiang, Xianghua Cui, Haoning Ma, Xiangsheng Tang
Summary: Denosumab outperforms zoledronic acid in delaying first-and-subsequent skeletal-related events, with lower incidence of renal toxicity and acute phase reaction, but higher incidence of hypocalcemia and osteonecrosis of the jaw in treating advanced cancer with bone metastasis. More randomized controlled trials are needed for further evaluation.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
(2021)
Article
Pharmacology & Pharmacy
B. He, J-Q Zhao, M-Z Zhang, Z-X Quan
Summary: Zoledronic acid significantly reduces the incidence of fracture and mortality at 24-month follow-up, but may increase adverse events such as serious atrial fibrillation and death from stroke.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Review
Cell Biology
Zachary S. Bernstein, E. Bridget Kim, Noopur Raje
Summary: Multiple Myeloma is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells in the bone marrow, often leading to bone disease and osteolytic lesions. Treatment options can include osteoclast inhibitory therapies to delay and reduce the risk of skeletal-related events.
Review
Surgery
Mei Liu, Shengqiang Qian, Jing Wu, Jing Xiao, Xiaohua Zeng
Summary: The meta-analysis suggests that the addition of Zoledronic acid (ZA) to neoadjuvant therapy does not improve the pathological complete response (pCR) rate in breast cancer patients. However, there might be a potential benefit in postmenopausal women and patients with triple-negative breast cancer. Furthermore, the use of ZA does not show benefits in objective response rate, breast-conserving surgery rate, or recurrence rate, and may increase the risk of mortality.
ASIAN JOURNAL OF SURGERY
(2023)
Review
Oncology
Luca Mastrantoni, Giovanna Garufi, Elena Di Monte, Noemi Maliziola, Mariangela Pasqualoni, Letizia Pontolillo, Sergio Pannunzio, Maria Chiara Cannizzaro, Armando Di Bello, Alessandra Fabi, Antonella Palazzo, Giampaolo Tortora, Emilio Bria, Armando Orlandi
Summary: In this study, the impact of Denosumab on survival outcomes in early breast cancer was evaluated through a systematic review and meta-analysis. The results showed that Denosumab did not improve disease-free survival, bone-metastasis-free survival, or overall survival in the overall population. However, a benefit in disease-free survival was observed in hormone receptor positive/HER2 negative breast cancer patients and an improvement in bone-metastasis-free survival in all hormone receptor positive patients. Bone-health outcomes were improved with no added toxicity.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Review
Endocrinology & Metabolism
Xiao Li, Jingru Han, Xiaotong Shi, Zhiguo Bi, Jianguo Liu
Summary: This meta-analysis assessed the efficiency and safety of Zoledronic acid (ZA) and denosumab for periprosthetic bone mineral density loss after total hip arthroplasty (THA). The results showed that treatment with ZA or denosumab significantly reduced periprosthetic BMD loss after THA, and no serious adverse events were observed.
ARCHIVES OF OSTEOPOROSIS
(2023)
Review
Oncology
Veronica Mollica, Alessandro Rizzo, Matteo Rosellini, Andrea Marchetti, Angela Dalia Ricci, Alessia Cimadamore, Marina Scarpelli, Chiara Bonucci, Elisa Andrini, Costantino Errani, Matteo Santoni, Rodolfo Montironi, Francesco Massari
Summary: Approximately 90% of patients with metastatic prostate cancer develop bone metastases, leading to various skeletal complications. The use of bone-targeted agents is a major focus in improving survival outcomes for these patients.
Article
Endocrinology & Metabolism
Margaret Zacharin, Angelina Lim, James Gryllakis, Aris Siafarikas, Craig Jefferies, Julie Briody, Natasha Heather, Janne Pitkin, Jaiman Emmanuel, Katherine J. Lee, Xiaofang Wang, Peter J. Simm, Craig F. Munns
Summary: The study found that using zoledronic acid in DMD patients significantly improved bone mineral density. Compared to the control group, the ZA group had a significantly higher LS BMD Z-score difference at 12 and 24 months, with no impact on pain, mobility, and bone turnover. Additionally, the ZA group showed improvements in pQCT measurements compared to the control group.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Editorial Material
Oncology
Laura T. Dickens, Ben Derman, Jason T. Alexander
Summary: This synopsis summarizes the Endocrine Society guidelines for hypercalcemia of malignancy in adults.
Article
Oncology
Jens-Uwe Blohmer, Theresa Link, Mattea Reinisch, Marianne Just, Michael Untch, Oliver Stotzer, Peter A. Fasching, Andreas Schneeweiss, Pauline Wimberger, Sabine Seiler, Jens Huober, Marc Thill, Christian Jackisch, Kerstin Rhiem, Christine Solbach, Claus Hanusch, Fenja Seither, Carsten Denkert, Knut Engels, Valentina Nekljudova, Sibylle Loibl
Summary: The study showed that adding denosumab to anthracycline/taxane-based neoadjuvant chemotherapy did not improve pCR rates, while using nab-paclitaxel at a dosage of 125 mg/m(2) weekly significantly increased the pCR rate.
Review
Nutrition & Dietetics
Khemayanto Hidayat, Jing-Si Chen, Tian-Ci Wang, Yu-Jie Liu, Yu-Jie Shi, Hong-Wen Su, Biao Liu, Li-Qiang Qin
Summary: This meta-analysis study suggests that milk supplementation can have a positive impact on hip and lumbar spine bone density, as well as reducing bone turnover markers and parathyroid hormone concentrations, potentially preventing bone loss.
ADVANCES IN NUTRITION
(2022)
Article
Medicine, General & Internal
Yuan Liu, Jia-Wen Xu, Ming-Yang Li, Li-Min Wu, Yi Zeng, Bin Shen
Summary: A meta-analysis of six RCTs suggests that ZA is beneficial in maintaining periprosthetic BMD in osteoporosis patients at 6 and 12 months after THA. The Harris Hip Score was significantly improved in ZA-treated patients. However, longer follow-up studies are needed to assess the survival of implants.
FRONTIERS IN MEDICINE
(2021)
Article
Oncology
Janson Trieu, Mark Chang, Vanessa Rojas, Neilmegh Varada, Yen Cao, Michael Anderson, Nicholas J. Vogelzang
Summary: Real-world analysis demonstrated a low fracture rate in mCRPC patients receiving Ra-223 and abiraterone or enzalutamide while on BHA, which may inform current clinical practice.
CLINICAL GENITOURINARY CANCER
(2022)
Article
Endocrinology & Metabolism
Weiwei Li, Zeqiong Ning, Zhifu Yang, Tingting Fan, Minna Yao, Wei Zhang, Mingming Wang, Aidong Wen, Jingwen Wang
Summary: This study compared the safety profiles of denosumab and zoledronic acid in the treatment of osteoporosis. The results showed that both drugs were equally effective in reducing the risk of drug-induced fractures, but denosumab had a lower incidence of composite cardiovascular disease, making it a better option for patients with cardiovascular disease.
ARCHIVES OF OSTEOPOROSIS
(2022)
Letter
Endocrinology & Metabolism
D. Rosenberg, T. Avni, G. Tsvetov, A. Gafter-Gvili, T. Diker-Cohen
Summary: This meta-analysis of 25 randomized controlled trials involving 21,523 patients showed that the risk of malignancy associated with denosumab treatment was similar to other comparators. Concerns regarding potential increased risk of malignancy from immunomodulatory effect of denosumab were not supported by the evidence from this study. Post-marketing surveillance will be crucial for detecting rare or late-occurring events since longer observation in randomized controlled trials is not expected.
OSTEOPOROSIS INTERNATIONAL
(2021)